# MMP-9 based immune-driven mechanisms of neovascular AMD

> **NIH NIH R01** · UNIVERSITY OF IOWA · 2024 · $540,439

## Abstract

PROJECT SUMMARY/ABSTRACT
The neovascular ‘wet’ form of age-related macular degeneration (nvAMD), whereby new blood vessels grow
under the retina, requires treatment with anti-vascular endothelial growth factor eye injections typically every 1-
3 months for the remainder of patients’ lives due to persistent fluid, which can be visualized and quantified by
optical coherence tomography (OCT) imaging. Recent research has implicated matrix metalloproteinase 9
(MMP9), expressed in immune cells of the retinal blood supply (termed choroid), as a mediator in the formation
and persistence of nvAMD. This proposal will elucidate our understanding of this novel immune-based
mechanism. Characteristics of patients with high-risk genotype of MMP9 will also be assessed, as they are
associated with incomplete response to standard therapies for nvAMD. We will identify genetic regulatory
regions that control expression of MMP9 and determine the immunologic activation profiles in patients with
nvAMD. We will use artificial intelligence (AI)-based approaches to associate phenotypic features observable
on OCT and OCT-angiography with high- and low-risk MMP9 genotypes in patients with nvAMD.
Our outstanding team of interdisciplinary researchers will collaborate to employ state-of-the-art genomic and
immunologic techniques to study the mechanisms of how MMP9 is implicated in nvAMD and fibrosis. Genetics
will aid AI- and machine learning-based analysis of OCT images to learn new features associated with the
most challenging patients afflicted with nvAMD. Unraveling the disease mechanisms associated with MMP9
will reveal new targets for therapeutic intervention. This proposal encompasses 5 of the 7 cross-cutting areas
of emphasis the NEI laid out in the 5-year Strategic Plan on November 1, 2021. This is the next, necessary
milestone in nvAMD that will help to address this major socioeconomic health burden.

## Key facts

- **NIH application ID:** 10913619
- **Project number:** 5R01EY035435-02
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Jon C.D. Houtman
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $540,439
- **Award type:** 5
- **Project period:** 2023-09-01 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10913619

## Citation

> US National Institutes of Health, RePORTER application 10913619, MMP-9 based immune-driven mechanisms of neovascular AMD (5R01EY035435-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10913619. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*